英国新生儿神经发育随访:现状调查与未来建议
该研究为2022年7–9月对英格兰、苏格兰和威尔士187个新生儿单位进行的在线调查,评估新生儿神经发育随访服务与英国国家卫生与临床优化研究所(NICE)指南NG72的一致性。共154个单位回应(82%),包括58个新生儿重症监护病房中的52个(89%)、86个本地新生儿单位中的68个(79%)和43个特殊护理婴儿单位中的34个(79%)。136个单位(88%)对出生<30周早产儿提供神经发育随访,75个单位(51%)对出生<32周早产儿提供;145个应答单位中134个(92%)对需降温治疗的脑损伤婴儿提供随访;129个单位(83%)对出生<30周早产儿提供2岁面对面神经发育评估,仅10个单位(6%)对出生<28周早产儿提供4岁评估;仅13个单位(9.6%)向家庭转介同伴支持服务。作者结论认为随访结构和内容差异大,缺乏4岁评估是错失支持入学准备的机会。
要点
- 154个新生儿单位回应调查(82%),136个单位(88%)对出生<30周早产儿提供神经发育随访,75个单位(51%)对出生<32周早产儿提供。
- 129个单位(83%)对出生<30周早产儿提供2岁面对面神经发育评估,仅10个单位(6%)对出生<28周早产儿提供4岁评估。
- 145个应答单位中134个(92%)对需降温治疗的脑损伤婴儿提供随访。
- 仅13个单位(9.6%)向家庭转介同伴支持服务。
- 作者认为缺乏4岁评估是错失支持入学准备的机会,临床政策与指南应进一步明确哪些服务最适合且负责提供该照护。
适用人群与场景
- 英格兰、苏格兰和威尔士的新生儿单位(n=187),应答单位为154个,包括新生儿重症监护病房、本地新生儿单位和特殊护理婴儿单位。
- 调查对象为负责神经发育随访的新生儿临床负责人。
研究设计与关键结果
- 设计为在线调查,2022年7–9月覆盖英格兰、苏格兰和威尔士187个新生儿单位,应答154个(82%),包括58个新生儿重症监护病房中的52个(89%)、86个本地新生儿单位中的68个(79%)、43个特殊护理婴儿单位中的34个(79%)。
- 136个单位(88%)对出生<30周早产儿提供神经发育随访,75个单位(51%)对出生<32周早产儿提供。
- 145个应答单位中134个(92%)对需降温治疗的脑损伤婴儿提供随访。
- 129个单位(83%)对出生<30周早产儿提供2岁面对面神经发育评估;仅10个单位(6%)对出生<28周早产儿提供4岁评估。
- 仅13个单位(9.6%)向家庭转介同伴支持服务。
证据类型、等级与局限
- 证据类型:在线调查(横断面调查)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为缺乏对出生<28周早产儿4岁时的神经发育监测与支持。
- 作者认为这些数据可为运营交付网络(ODNs)了解本地区新生儿神经发育随访的提供方式提供证据,帮助告知家庭可用服务、促进联合工作,并在英国提供更公平的新生儿随访。
- 作者认为临床医生可通过指引家庭获取可信的本地、社区、在线或第三部门支持来改善与家庭的信息共享。
- 作者认为需要进一步研究从父母/照护者视角以及系统与流程视角全面了解新生儿和儿科发育服务。
- 作者认为临床政策与指南应进一步明确哪些服务最适合且负责提供该照护。
指南或共识出处
- 英国国家卫生与临床优化研究所(NICE)指南NG72《早产儿童和青少年发育随访》
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To assess the clinical service provision of neonatal follow-up services in the UK in line with UK National Institute for Health and Care Excellence (NICE) guideline NG72, 'Developmental follow-up of children and young people born preterm'.
METHODS: Design: Online survey.
SETTING: Neonatal units in England, Scotland and Wales (n = 187) in July- September 2022.
PARTICIPANTS: Lead neonatal clinicians for neurodevelopmental follow-up.
RESULTS: Responses were received from 154 neonatal units, representing 82% of the total. This included 52 out of 58 (89%) Neonatal Intensive Care Units, 68 out of 86 (79%) Local Neonatal Units, and 34 out of 43 (79%) Special Care Baby Units. In total, 136 units (88%) provided neurodevelopmental follow-up for infants born before 30 weeks' gestation, and 75 units (51%) did so for those born before 32 weeks' gestation. Out of 145 responses, 134 units (92%) offered follow-up to infants with brain injury requiring cooling therapy. A 2-year neurodevelopmental face-to-face appointment was available for infants born before 30 weeks' gestation in 129 units (83%), while only ten units (6%) provided a 4-year assessment for those born before 28 weeks' gestation. Additionally, just 13 units (9.6%) directed families to peer support services.
CONCLUSIONS: The structure and content of neonatal neurodevelopmental follow-up vary widely. Notably, there is a lack of 4-year assessments for infants born preterm, representing a missed opportunity to support school readiness.
KEY MESSAGES: What is already known on this topic? Neonatal neurodevelopmental follow-up is a vital aspect of care for early detection of difficulties, timely access to intervention, promotion of long-term health and wellbeing and data collection to contribute to parental counselling. Delivery of neonatal follow-up in line with UK clinical guidelines has not been evaluated. What this study hopes to add. There is wide variation in the inclusion criteria, content, and duration of neonatal neurodevelopmental follow-up in the UK. Only 6.8% of services reported offering infants born < 28 weeks' gestation a face-to-face appointment at four years of age. Recognition that the informational needs of parents may be conflated with the data requirements of clinicians, and this may contribute to suboptimal clinical service provision and limited reliable outcome data. How this study might affect research, practice, or policy. This study highlights the lack of neurodevelopmental surveillance and support for children born < 28 weeks' gestation at four years of age. These data provide evidence for Operational Delivery Networks (ODNs) to understand how neonatal neurodevelopmental follow-up is delivered within their area. This will help inform families about available services, facilitate joint work, and deliver more equitable neonatal follow-up in the UK. Clinicians could improve information sharing with families by signposting to trusted local, community, online, or third-sector support. Further research is necessary to comprehensively understand neonatal and paediatric developmental services from a parent/caregiver perspective and a systems and processes perspective. Clinical policy and guidelines should provide further clarity regarding which services are most appropriate and responsible for delivering this care.
参考来源
- Marcroft C, Cruickshank H, Johnson S, et al. Neonatal neurodevelopmental follow-up in the UK: a survey of current practice and future recommendations. BMC Pediatr. 2025. PMID: 40890728. doi:10.1186/s12887-025-05960-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。